Somatostatin analogue for acromegaly (lanreotide first-generation SSA; pasireotide for SSA-refractory disease)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-LANREOTIDE |
|---|
| ID | REG-SSA-ACROMEGALY |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-07-11 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-CNS-2025 SRC-NCCN-NET-2025 |
Notes
STUB pending clinical co-lead signoff (CHARTER §6.1). Lanreotide modeled as the representative first-generation SSA per the Disease narrative ("somatostatin analogs (octreotide LAR, lanreotide, pasireotide LAR)"), mirroring the identical modeling choice already made in REG-LANREOTIDE-AUTOGEL-GI-NET / ALGO-PNET-METASTATIC-1L / ALGO-GI-NET-ADVANCED-1L. Octreotide LAR is an equivalent alternative first-generation SSA but DRUG-OCTREOTIDE does not yet exist in this KB (previously flagged as a deferred item in those sibling algorithms) — not authored here to stay within this task's scope; open gap noted on DIS-PITUITARY-ADENOMA.
Used By
Indication
IND-PITUITARY-ADENOMA-1L-ACROMEGALY-SURGERY-SSA- IND-PITUITARY-ADENOMA-1L-ACROMEGALY-SURGERY-SSA